107例培门冬酶药品不良反应临床病例及文献分析

摘要/Abstract

摘要： 目的了解培门冬酶致药品不良反应（ADR）的发生情况与临床特点,为临床安全用药提供参考。方法收集中国医学科学院血液病医院2013年7月至2019年3月使用培门冬酶出现ADR的病例,并检索中国知网（CNKI）、维普中文期刊全文数据库（VIP）、万方数据库及Pubmed数据库中关于培门冬酶致ADR的个例报道,将所有病例的患者性别、年龄、原患疾病、用药情况、ADR发生时间等进行汇总分析。结果经筛选后共纳入107例,包括我院临床病例30例及文献报道病例77例。其中,男性67例（62.62%）,女性40例（37.38%）,10岁以下儿童占比最大（51.40%）。ADR发生于用药后3分钟至44天,临床表现以胃肠系统损害、血液系统损害和心血管系统损害最多。结论临床医师和药师应重视培门冬酶ADR的发生特点,在应用培门冬酶时,严密监测患者临床症状及凝血功能、肝功能等相关指标,以尽量降低ADR对患者造成的损害。

关键词: 培门冬酶, 药品不良反应, 临床病例分析, 文献分析

Abstract: Objective To analyze the occurrence and clinical characteristics of adverse drug reactions induced by pegaspargase, so as to provide reference for clinical safe medication. Methods ADR cases induced by pegaspargase in the Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences from July 2013 to March 2019 were collected. In addition, case reports of adverse drug reactions induced by pegaspargase were retrieved from the CNKI database, VIP database, Wanfang database and Pubmed database. Then patients information such as gender, age, original disease, medication and the occurrence of adverse reactions was summarized and analyzed. Results Totally 107 patients were retrieved, including 30 clinical cases in our hospital and 77 literature cases. Among them, 67(62.62%) were males and 40(37.38%) were females, and 55(51.40%) were children under 10 years old. Adverse reactions occurred in 3 minutes to 44 days after administration of pegaspargase. The main clinical manifestations were gastrointestinal damage, blood system damage and cardiovascular damage. Conclusion Clinicians and pharmacists should pay attention to the occurrence characteristics of adverse reactions of pegaspargase. When using chemotherapy regimens containing pegaspargase, it should be closely observed the clinical symptoms and monitored related indicators such as coagulation function and liver function, in order to minimize the adverse drug reactions damage caused by pegaspargase.

Key words: pegaspargase, adverse drug reactions, clinical case analysis, literature analysis

中图分类号:

R994.11

苗文娟, 田稷馨, 于雅晴, 章萍. 107例培门冬酶药品不良反应临床病例及文献分析[J]. 中国药物警戒, 2019, 16(6): 367-373.

MIAO Wenjuan, TIAN Jixin, Yu Yaqing, ZHANG Ping. Clinical and Literature Analysis of 107 Cases of Adverse Drug Reactions Induced by Pegaspargase[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 367-373.

参考文献

[1] 中国临床肿瘤学会,中华医学会血液学分会,中华儿科血液学分会. 培门冬酶治疗急性淋巴细胞白血病和恶性淋巴瘤的专家共识[J]. 临床肿瘤学杂志, 2013,18(3):256-263.
[2] 范平平, 崔昊,王文君. 培门冬酶注射液致儿童胰腺炎3例[J]. 中国药物警戒, 2015,12(6):376.
[3] 陈秋蓉,邓莹迎. 1例培门冬酶诱发急性胰腺炎的护理体会[J]. 中国实用护理杂志, 2014,30(z2):116-117.
[4] 赖长城,李艳红,梁昌达. 门冬酰胺酶相关急性胰腺炎6例[J]. 实用医学杂志, 2017,33(21):3678-3679.
[5] 李太霞,祖慧娟,孙桂霞,等. 培门冬酶治疗急性淋巴细胞白血病并发急性胰腺炎1例护理体会[J]. 大家健康, 2011,5(6):43-45.
[6] 颜卫源,王丽杰. 脉搏指示连续心排血量监测技术救治重症胰腺炎并发急性呼吸窘迫综合征患儿两例[J]. 中华儿科杂志, 2014,52(9):693-698.
[7] 任文静,沈伟,张婉璐,等. 培门冬酶致出凝血功能异常、急性胰腺炎并重度脂肪肝1例[J]. 军事医学, 2017,41(1):80.
[8] 胡蓉华,孙婉玲,冀冰心,等. 培门冬酶致肝脂肪变性1例[J]. 中国药物警戒, 2013,10(3):185-186.
[9] 庞露,刘卓刚,朱珂,等. 门冬酰胺酶致高三酰甘油血症二例报告并文献复习[J]. 中华血液学杂志, 2015,36(1):70-72.
[10] 赵源,乔逸,白娟,等. 培门冬酶注射液致2例患者凝血障碍原因的分析[J]. 抗感染药学, 2015,12(2):245-247.
[11] 吴智绚,蔡伟,熊昊. 一例培门冬酶致低血糖性抽搐的护理[J]. 中国实用护理杂志, 2016,32(2):127-128.
[12] 李静,曹翠明,魏芳芳. 培门冬酶注射液致过敏性休克[J]. 中国药物应用与监测, 2012,9(2):119-120.
[13] 陈迎秋,刘双燕,戴小忠. 培门冬酶治疗儿童急性淋巴细胞白血病致过敏性休克1例[J]. 中国乡村医药, 2016,23(17):44.
[14] 洪雪佩,潘婧婧,季林梅. 培门冬酶致过敏性休克1例[J]. 浙江实用医学, 2015,20(4):305.
[15] 李文博. 培门冬酶治疗儿童急性淋巴细胞白血病致过敏一例[J]. 实用药物与临床, 2017,20(7):861-862.
[16] 张莉,舒鹤,李冰,等. 培门冬酶治疗儿童急性淋巴细胞白血病致过敏反应一例[J]. 中国医院药学杂志, 2015,35(18):1711-1712.
[17] 刘彩艳,贾冬梅. 1例培门冬酶注射液致过敏性休克成功救治的护理体会[J]. 当代护士, 2018,25(8):153-154.
[18] 刘志敏. 培门冬酶致皮肤过敏反应1例[J]. 临床肿瘤学杂志, 2016,21(2):191-192.
[19] 王丽,廖桂萍,尹晓林. 培门冬酶引起的静脉窦血栓形成一例[J]. 白血病·淋巴瘤, 2014,23(5):319-320.
[20] 宋亮,潘华,孙立荣. 急性淋巴细胞白血病患儿应用培门冬酶期间中枢神经系统损伤6例分析[J]. 中国小儿血液与肿瘤, 2015,20(2):95-99.
[21] Talamo L, Douvas M, Macik B G, et al.Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management[J]. Ann Hematol, 2017,96(4):691-693.
[22] Galindo R J, Yoon J, Devoe C, et al.PEG-asparaginase induced severe hypertriglyceridemia[J]. Arch Endocrinol Metab, 2016,60(2):173-177.
[23] Lu G, Karur V, Herrington J D, et al.Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine[J]. Proc(Bayl Univ Med Cent), 2016,29(1):46-47.
[24] Vyas N, Ching Companioni R, Tiba M, et al. Pegaspargase induced hypertriglyceridemia resulting in severe fatal pancreatitis[J/OL]. Case Rep Gastrointest Med, (2015-11-12)[2019-05-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677038.
[25] Shmookler A, Smith S.Pegaspargase-induced hypertriglyceridemia[J]. J Clin Apher, 2018,33(1): 97-98.
[26] Tang E R, Chapman T, Finn L S, et al.Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase[J]. Radio Case Rep, 2018,13(3):568-572.
[27] Sui J R, Zhang Y M, Yang L Q, et al.Successful treatment with rivaroxaban of cerebral venous thrombosis and bone marrow necrosis induced by pegaspargase: A case report and literature review[J]. Medicine, 2017,96(46):e8715.
[28] Buie LW, Moore J, Van Deventer H.Successful use of octreotide as a chemoprotectant for prevention of Peg-asparaginase-induced pancreatitis[J]. Pharmacotherapy, 2014,34(8):e149-e151.
[29] Plander M, Szendrei T, Bodó I, et al.Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment[J]. Ann Hematol, 2015,94(7):1257-1258.
[30] Kaminski K S, Beach C L, Peden D B, et al. Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia[J]. J Oncol Pharm Pract, 2016,22(2)354-356.
[31] Qubty W F, Mrelashvili A, Patterson M C.Epidural hematoma in a patient on pegylated-L-asparginase therapy[J]. J Child Neurol, 2015,30(5):636.
[32] Nussbaum V, Lubcke N, Findlay R.Hyperammonemia secondary to asparaginase: A case series[J]. J Oncol Pharm Pract, 2016,22(1):161-164.
[33] Vetro C, Giulietti G, Calafiore V, et al.A snapshot of asparaginase-induced liver insufficiency[J]. Eur J Haematol, 2013,92(3): 271-272.
[34] Sahiner U M, Yavuz S T, G kce M, et al. Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: Premedication and desensitization may not be sufficient[J]. Pediatr Int, 2013,55(4):531-533.
[35] Bostrom B.Successful Management of Extreme Hypertriglyceridemia from Pegaspargase with Omega-3[J].Pediatr Blood Cancer, 2012,59(2):350.
[36] Lashkari H P, Lancaster D, Atra A, et al.Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?[J]. Int J Hematol, 2011,94(6):571-575.
[37] Creel A M, Crawford D, Prabhakaran P, et al.Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia[J]. Pediatr Emerg Care, 2008,24(11):771-773.
[38] Dietel V, B hrdel P, Hirsch W, et al. Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia[J]. Klin Padiatr, 2007,219(2):95-96.
[39] Lawson E B, Gottschalk M, Schiff D E.Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report[J]. J Pediatr Hematol Oncol, 2011,33(2):e83-e86.
[40] Van Galen K P, Zweegman S, Ossenkoppele G J. Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase[J]. Br J Haematol, 2011,152(6):676.
[41] Bushara K O, Rust R S.Reversible MRI lesions due to pegaspargase treatment of Non-Hodgkin's lymphoma[J]. Pediatr Neurol, 1997,17(2):185-187.
[42] Kim S.Two cases of pegylated asparaginase-associated severe and persistent hyperbilirubinemia[J]. Am J of Hematol,2009,84(10):696.
[43] Alvarez O A, Zimmerman G.Pegaspargase-induced pancreatitis[J] Med Pediatr Oncol, 2000,34(3):200-205.
[44] Hinson A, Newbern D, Linardic C M. Asparaginase-induced hypertriglyceridemia presenting as pseudohyponatremia during leukemia treatment[J/OL]. Case Rep Pediatr, (2014-09-27)[2019-05-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227320.
[45] Kheder J, Han S, Wassef W Y.Successful endoscopic pancreatic necrosectomy in 5-year-old child[J]. Am J Gastroenterol, 2016,111(3):443-444.
[46] Winkler B, Kuhn S, Kunzmann S, et al.Severe hypertriglyceridemia in a 6-year-old boy with ALL relapse: successfully treated with plasmapheresis[J].Klin Padiatr, 2013,225(6):364-365.
[47] Lau K M, Saunders I M, Goodman A. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia[J/OL]. J Oncol Pharm Pract, (2019-02-04)[2019-05-07]. http://sage.cnpereading.com/paragraph/download/10.1177/1078155219833438.
[48] Pidapartiy M, Bostrom B.Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly[J]. Pediatr Blood Cancer, 2012,59(3):436-439.
[49] 倪雄,沈志祥,陈芳源,等. 2002-2006年上海市急性淋巴细胞白血病流行病学调查[J]. 中华血液学杂志, 2010,31(1):21-24.
[50] Lebovic R, Pearce N, Lacey L, et al.Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU[J]. Pediatr Blood Cancer, 2017,64(10):e26555.
[51] 张羽,何彦瑶,吴攀. 培门冬酶及左旋门冬酰胺酶治疗儿童急性淋巴细胞白血病的疗效及不良反应[J]. 临床药物治疗杂志, 2018,16(10):45-49.
[52] 丛佳,杨磊,叶进. 培门冬酶治疗淋巴系统肿瘤的不良反应及处理:来自单中心443例次的经验[J]. 中国血液学杂志, 2018,39(8):654-660.
[53] Tokimasa S, Yamato K.Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?[J]. Br J Haematol, 2012,157(3):381-382.